Key Highlights

● Moderna closed at $225.00, its highest level since 2021.

● BioNTech climbed to about $92.44 and Arcturus to about $14.10.

● Moderna replaced Warner Bros. Discovery in the Nasdaq-100.

● The 10-year Treasury yield remains near a 24-year high.

Messenger RNA, or mRNA, became a household term during the Covid-19 pandemic, when vaccines built on the technology were developed and rolled out at remarkable speed. As pandemic demand faded, so did investor enthusiasm, and companies that rode the boom spent years searching for their next big market.

On Friday, that market looked like cancer. A report said the National Institutes of Health is planning a public-private initiative, starting in December, to fast-track cancer vaccine research, with an initial focus on pancreatic, liver and colorectal cancers and some childhood tumours. The report said the effort aims to replicate the success of the Covid-19 vaccine push.

For mRNA developers, the parallel was hard to miss. The same speed and flexibility that made the technology useful against a fast-moving virus is what scientists hope to apply to personalised cancer treatments.

Moderna's breakout

Moderna (NASDAQ:MRNA) was the headline mover, soaring $28.00 to close at $225.00, its highest level since 2021. Volume of about 28.9 million shares was well above the 17.7 million average. The stock has already posted a multi-fold gain this year, according to market data, making it one of the market's standout performers of 2026.

Friday also marked Moderna's official entry into the Nasdaq-100, replacing Warner Bros. Discovery (NASDAQ:WBD). Some coverage linked part of the move to that index inclusion, while others pointed to the report. Index inclusion typically brings buying from funds that track the benchmark.

BioNTech and Arcturus follow

BioNTech (NASDAQ:BNTX), Moderna's main rival in mRNA and Pfizer (NYSE:PFE)'s partner on its Covid vaccine, climbed to about $92.44. Arcturus Therapeutics (NASDAQ:ARCT), a smaller mRNA developer, jumped to about $14.10 after Leerink Partners analyst Lili Nsongo reiterated an Outperform rating and raised the price target to $19 from $13.

Pfizer, which co-developed its Covid vaccine with BioNTech, also rose.

Not only mRNA

The comeback extended to vaccine makers using other technologies. Novavax (NASDAQ:NVAX), whose Covid vaccine is protein-based rather than mRNA, soared, though no company announcement or filing accounted for the move. Vaxcyte also climbed. The breadth showed investors were buying the vaccine theme broadly rather than picking winners based on technology.

Reasons for caution

The initiative has not been officially detailed, and no funding amounts or corporate partners were confirmed on Friday. Cancer vaccines remain an area of active research, and timelines in drug development are long. Friday's moves reflect expectations about a programme that has yet to begin.

Funding conditions matter too. The 10-year Treasury yield remains near a 24-year high, and the Fed raised rates in September for the first time since 2023, which raises the cost of capital for companies that spend heavily on research long before they earn steady profits.

Wider conditions were supportive, however. Health care was one of the best S&P 500 sectors on the day, and the S&P 500 rose 46.18 points to 7,811.54.

Funding Costs Remain a Headwind for Pre-Profit Developers

The next catalyst is any formal NIH announcement on the initiative ahead of its planned December start. Johnson & Johnson (NYSE:JNJ) reports on Tuesday, October 13, giving an early read on pharma earnings. September consumer prices are due Wednesday, October 14. US stocks trade on Monday, October 12, while the bond market is closed for Columbus Day. The Fed meets October 27–28.